Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francisco Cervantes, Nelson Spector, MD PhD, Brian Leber, MD, Susan Branford, PhDFFSc (RCPA), Tara A. Glynos, BS, Sandip Acharya, MSc, Darshan Dalal, MD PhD MPH, Jeffrey H. Lipton, MD PhD

Blood (2015) 126 (23): 4029.

https://doi.org/10.1182/blood.V126.23.4029.4029

Published: 2015

Journal Articles

Initial Molecular Response At 3 Months Can Identify Three Groups Of Patients With Different Responses and Event-Free Survival At 36-Months Following Second-Generation Tyrosine Kinase Inhibitor Therapy In Imatinib-Resistant Chronic Myeloid Leukemia

Carla Boquimpani, MD, Rony Schaffel, MD, PhD, Daniel Graça, Camila Mesquita, Tania Silva Madeira, MD, Danielle Peixoto, MD, Patricia Wendling, MD, Clarisse Lobo, MD, Irene Biasoli, MD, PhD, Nelson Spector, MD, PhD

Blood (2013) 122 (21): 4005.

https://doi.org/10.1182/blood.V122.21.4005.4005

Published: 2013

Journal Articles

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Brian Leber, MD, Francisco Cervantes, MD, PhD, Nelson Spector, MD, PhD, Jeffrey H. Lipton, MD, PhD, Gabriel Etienne, MD, PHD, Ricardo Pasquini, MD, PhD, Nelma Christina Clementino, MD, Agnès Guerci-Bresler, MD, Donna Forrest, MD, FRCPC, Anthony P. Schwarer, MD, Sandip Acharya, LaTonya Collins, BSN, Tomasz Szczudlo, Timothy P. Hughes, MD, MBBS

Blood (2013) 122 (21): 94–95.

https://doi.org/10.1182/blood.V122.21.94.94

Published: 2013

Journal Articles

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Nelson Spector, MD, PhD, Brian Leber, MD, Ricardo Pasquini, MD, PhD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Gabriel Etienne, MD, PhD, Agnès Guerci-Bresler, MD, Susan Branford, PhD, Das Purkayastha, LaTonya Collins, BSN, Tomasz Szczudlo, Francisco Cervantes, MD, PhD

Blood (2012) 120 (21): 694.

https://doi.org/10.1182/blood.V120.21.694.694

Published: 2012

Journal Articles

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Timothy P. Hughes, MD, MBBS, Jeffrey H. Lipton, MD, PhD, Brian Leber, MD, Nelson Spector, MD, PhD, Francisco Cervantes, MD, PhD, Ricardo Pasquini, MD, Nelma Clementino, MD, Anthony P. Schwarer, MD, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Suzanne Kamel-Reid, PhD, Israel Bendit, MD, John Reynolds, PhD, Lisa Williams, Tomasz Szczudlo, Susan Branford, PhD

Blood (2011) 118 (21): 606.

https://doi.org/10.1182/blood.V118.21.606.606

Published: 2011

Journal Articles

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

Blood (2011) 118 (21): 1701.

https://doi.org/10.1182/blood.V118.21.1701.1701

Published: 2011

Journal Articles

The Number of CD4+ T-Lymphocytes in the Autograft Correlates with Outcome After Autologous Stem-Cell Transplantation in Relapsed Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

Rony Schaffel, MD, PhD, Maria L.S. Lima, Adrienne B.M. Madureira, MD, Nelson Spector, MD, PhD, Helio S. Dutra, PhD

Blood (2009) 114 (22): 3422.

https://doi.org/10.1182/blood.V114.22.3422.3422

Published: 2009

Journal Articles

FLT3 Internal Tandem Duplications in Adults with De Novo Acute Myeloid Leukemia.

Sandra G. Xavier, MD, Rocío Hassan, PhD, Nelma C.D. Clementino, MD, PhD, Daniel G. Tabak, MD, Nelson Spector, MD, PhD, Ilana R. Zalcberg, MD, PhD

Blood (2004) 104 (11): 4430.

https://doi.org/10.1182/blood.V104.11.4430.4430

Published: 2004

Journal Articles

Characteristics and Outcomes of Critically Ill Patients with Hematologic Malignancies.

Marcio Soares, MD, Jose R. Rocco, MD, PhD, Nelson Spector, MD, PhD

Blood (2004) 104 (11): 5288.

https://doi.org/10.1182/blood.V104.11.5288.5288

Published: 2004

NARROW

Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)

Initial Molecular Response At 3 Months Can Identify Three Groups Of Patients With Different Responses and Event-Free Survival At 36-Months Following Second-Generation Tyrosine Kinase Inhibitor Therapy In Imatinib-Resistant Chronic Myeloid Leukemia

Achievement and Maintenance Of Deeper Molecular Response By Switching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Residual Disease On Long-Term Imatinib: ENESTcmr 36-Month Follow-Up

Switching to Nilotinib Is Associated with Continued Deeper Molecular Responses in CML-CP Patients with Minimal Residual Disease After ≥ 2 Years On Imatinib: Enestcmr 2-Year Follow-up Results

Complete Molecular Response (CMR) Rate with Nilotinib in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) without CMR After ≥ 2 Years on Imatinib: Preliminary Results From the Randomized ENESTcmr Trial of Nilotinib 400 Mg Twice Daily (BID) Vs Imatinib

Bcr-Abl Mutations in Chronic Myeloid Leukemia - Impact on Survival and Treatment with Second Generation Inhibitors– A Study on Behalf of Latin American Leukemia Net (Lalnet)

The Number of CD4+ T-Lymphocytes in the Autograft Correlates with Outcome After Autologous Stem-Cell Transplantation in Relapsed Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma.

FLT3 Internal Tandem Duplications in Adults with De Novo Acute Myeloid Leukemia.

Characteristics and Outcomes of Critically Ill Patients with Hematologic Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only